Brenntag lifts 2026 profit outlook, shares trade lower after strong guidance

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 13:13.

Brenntag (DE000A1DAHH0) tightened its narrative on earnings this week by raising its full-year 2026 operating EBITDA guidance after a stronger-than-expected second quarter. The stock trades on Xetra and has come under pressure despite the upgrade, as analyst commentary and profit-taking weigh on the shares.Investing.com analysis of the Q2 beat and guidance raise

What Brenntag reported on Q2

The Essen-based chemicals distributor disclosed preliminary second-quarter operating EBITDA of around 450 million euros, markedly above the prior-year level of 334 million euros and ahead of analyst expectations.Wirtschaftswoche summary of Brenntag's preliminary Q2 figures Vara Research had compiled a consensus mean of roughly 366.9 million euros from eight analysts as of June 22, underlining the scale of the beat.Investing.com citing Vara Research consensus on Brenntag

Jefferies calculated that the preliminary figure equates to around 35 percent year-on-year growth and a 27 percent beat versus its own estimate of 353 million euros, putting the quarter clearly above internal expectations.Jefferies commentary quoted by Investing.com Brenntag attributed the performance to robust current demand and improved margins, particularly in the context of supply-chain disruptions linked to the crisis in the Middle East, which have supported pricing in certain product streams.Handelsblatt newsblog on Brenntag's profit guidance increase

The new 2026 guidance and consensus view

On the back of the Q2 beat, Brenntag raised its full-year 2026 operating EBITDA guidance to a range of 1.25 billion to 1.40 billion euros, compared with the previous corridor of 1.15 billion to 1.35 billion euros.Investing.com report on Brenntag's updated guidance range Jefferies noted that the new range lines up with the broader consensus at the midpoint, citing a 1.332 billion euro consensus operating EBITDA forecast for 2026.Jefferies view on Brenntag consensus levels

Despite the guidance lift, management emphasized a cautious tone, pointing to continued uncertainty and the risk of demand weakness in the second half of the year.Management comments on macro risks reported by Investing.com The company’s stance reflects both the temporary benefits from the Middle East crisis and concerns that structural headwinds in the European chemicals market could reassert themselves once the short-term disruption fades.Wirtschaftswoche interpretation of Brenntag's demand backdrop

How analysts react to Brenntag

The guidance change has triggered a series of analyst notes, with views ranging from cautious to constructive. Jefferies maintained a Hold rating on Brenntag, setting a price target of 56 euros, which represents modest upside from a prior closing level around 53.90 euros.Jefferies rating and target reported by Investing.com

Deutsche Bank’s Tristan Lamotte kept a Neutral stance with a 57 euro target price, following an earlier downgrade in mid-June from Buy to Hold as valuation and cyclicality concerns mounted.Deutsche Bank research note summarized on MarketScreener UBS has reiterated its Neutral rating as well, while JP Morgan continues to apply a Sell recommendation, viewing Brenntag as one of the weaker names in its European chemicals coverage amid structural headwinds.MarketScreener aggregation of UBS and JP Morgan stances on Brenntag

Where Brenntag shares trade today

Despite a strong reaction on Tradegate immediately after the guidance announcement, where the shares rose about 3.5 percent above the Xetra close in early trade, the stock has given back these gains in subsequent sessions.dpa-AFX broker report on Brenntag's Tradegate move On Xetra, Brenntag currently trades around 53.12 euros, down roughly 4.6 percent from the previous day's level of 55.64 euros, according to finanzen.net real-time data.Finanzen.net real-time quote for Brenntag

The stock sits in the DAX, making it a core holding in many German equity portfolios.Finanzen100 profile of Brenntag as a DAX constituent Over the past month, the shares have still posted a positive performance despite the latest pullback, helped by optimism around the earnings trajectory and the repositioning of consensus after the profit guidance increase.MarketScreener performance data on Brenntag

The business behind Brenntag

Brenntag's core business is the global distribution of chemicals and ingredients, connecting producers with industrial and specialty customers across sectors such as food, pharmaceuticals, coatings, and oil and gas.Company overview on Brenntag's corporate site A representative offering is its portfolio of specialty chemical solutions for water treatment, where Brenntag bundles chemicals, logistics and technical service to help industrial plants and municipalities manage their water quality and effluent discharge.Brenntag water treatment solutions product page

The company operates a large network of warehouses, blending facilities and laboratories globally, which enables it to respond quickly to supply-chain disruptions and regional demand patterns.Brenntag Investor Relations presentations on its network This infrastructure is central to the earnings story: in volatile markets, Brenntag can leverage its scale and logistics capabilities to secure product availability and capture margin opportunities when transport routes or production in certain regions are constrained.Handelsblatt on Brenntag benefiting from Middle East market disruptions

The listing and current price snapshot

The Brenntag shares (DE000A1DAHH0) trade on Xetra at 53.12 euros as of 2026-06-23, 11:19, according to finanzen.net, with a bid of 53.12 euros and an ask of 53.16 euros.Finanzen.net Xetra price and time stamp for Brenntag The current level reflects a daily decline of about 4.6 percent versus the prior close of 55.64 euros, underlining that investors are taking a cautious view of the guidance upgrade.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data and opinions are based on sources deemed reliable at the time of publication but may change without notice.